Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.86% | 229.33% | 194.50% | 109.44% | 64.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.57% | 41.58% | 65.22% | 37.86% | 69.05% |
| Operating Income | -1.57% | -41.58% | -65.22% | -37.86% | -69.05% |
| Income Before Tax | 71.17% | 16.30% | 90.97% | -270.52% | 24.13% |
| Income Tax Expenses | 210.00% | -- | -- | -- | 0.00% |
| Earnings from Continuing Operations | 70.11% | 16.30% | 90.97% | -270.52% | 24.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.11% | 16.30% | 90.97% | -270.52% | 24.27% |
| EBIT | -1.57% | -41.58% | -65.22% | -37.86% | -69.05% |
| EBITDA | -1.59% | -41.47% | -65.20% | -37.52% | -68.98% |
| EPS Basic | 89.26% | 75.94% | 97.16% | -42.18% | 50.24% |
| Normalized Basic EPS | 89.66% | 75.94% | 97.17% | -42.17% | 50.14% |
| EPS Diluted | 89.33% | 73.91% | 79.99% | -42.18% | 49.93% |
| Normalized Diluted EPS | 89.66% | 76.22% | 97.29% | -42.17% | 50.14% |
| Average Basic Shares Outstanding | 178.58% | 247.84% | 218.08% | 160.60% | 52.19% |
| Average Diluted Shares Outstanding | 178.58% | 251.89% | 232.52% | 160.60% | 52.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |